Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
PartnerLondon, United Kingdom
Laptaria cu Caimac has completed an IPO
Laptaria cu Caimac has raised US$5 million through a private placement of shares on the ATS Market of BSE. The funds will be used for the development of the factory, namely, the construction of a bottle and jar washing station, utility systems and packaging storage.Learn more
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.Learn more
Crimson Tide has completed a primary placing and secondary sell-down
Crimson Tide Plc has raised funds to invest in further developing its core product, in a new product aimed at micro/nano businesses and in marketing capabilities.Learn more